McN-JR 4749 en es it fr

McN-JR 4749 Brand names, McN-JR 4749 Analogs

McN-JR 4749 Brand Names Mixture

  • No information avaliable

McN-JR 4749 Chemical_Formula


McN-JR 4749 RX_link

McN-JR 4749 fda sheet

McN-JR 4749 msds (material safety sheet)

McN-JR_4749 MSDS

McN-JR 4749 Synthesis Reference

No information avaliable

McN-JR 4749 Molecular Weight

166.24 g/mol

McN-JR 4749 Melting Point

No information avaliable

McN-JR 4749 H2O Solubility

Appreciable as liquid hydrochloride salt

McN-JR 4749 State


McN-JR 4749 LogP


McN-JR 4749 Dosage Forms

Liquid for injection

McN-JR 4749 Indication

For the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises.

McN-JR 4749 Pharmacology

Edrophonium is a short and rapid-acting anticholinesterase drug. Its effect is manifest within 30 to 60 seconds after injection and lasts an average of 10 minutes. Edrophonium's pharmacologic action is due primarily to the inhibition or inactivation of acetylcholinesterase at sites of cholinergic transmission. Muscarinic receptors are found throughout the body, especially on muscle. Stimulation of these receptors causes to muscle contraction. In myasthenia gravis the body's immune system destroys many of the muscarinic receptors, so that the muscle becomes less responsive to nervous stimulation. Edrophonium chloride increases the amount of acetylcholine at the nerve endings. Increased levels of acetyl choline allow the remaining receptors to function more efficiently.

McN-JR 4749 Absorption

Rapidly absorbed.

McN-JR 4749 side effects and Toxicity

With drugs of this type, muscarine-like symptoms (nausea, vomiting, diarrhea, sweating, increased bronchial and salivary secretions and bradycardia) often appear with overdosage (cholinergic crisis).

McN-JR 4749 Patient Information

No information avaliable

McN-JR 4749 Organisms Affected

Humans and other mammals